References
- Peinert S, Tam CS, Prince MH, et al. . Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leuk Lymphoma 2010;51:2188–2197.
- Dhodapkar MV, Hoering A, Gertz MA, et al. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009;113:793–796.
- Treon SP, Branagan AR, Ioakimidis L, et al. . Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113:3673–3678.
- Ghobrial IM, Xie W, Padmanabhan S, et al. . Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010;85:670–674.
- Baehring JM, Hochberg EP, Raje N, Ulrickson M, HochbergFH. Neurological manifestations of Waldenstrom macroglobulinemia. Nat Clin Pract Neurol 2008;4:547–556.
- Nowis D, Maczewski M, Mackiewicz U, et al. . Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658–2668.
- Ghobrial IM, Gertz M, Laplant B, et al. . Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408–1414.
- Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 2009;31:2290–2311.
- Eve HE, Seymour JF, Rule SA. Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/− rituximab. Leuk Lymphoma 2009;50:463–465.
- Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28:2227–2232.
- Levy V, Porcher R, Leblond V, et al. . Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis. Leukemia 2001;15:1466–1470.